Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Andrew Dunn

Senior Biopharma Correspondent

The AI-focused biotech Generate:Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss drugmaking giant Novartis.

Novartis will pay …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

Exclusive: Constructive Bio raises $58M for synbio work, and Nobel laureate joins board

House passes reauthorization of rare pediatric voucher program

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Flag­ship’s AI biotech Gen­er­ate lands $65M up­front in No­var­tis deal, as first clin­i­cal read­outs near

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near